M802

M802 (0-50 nM) specifically binds to the purified extracellular domains of human HER2 and CD3, with high affinity for HER2 (K_d = 0.578 nM) and lower affinity for CD3 (K_d = 71.2 nM), and possesses dual binding capacity to simultaneously bind both antigens^[1].
M802 (0.001-1000 nM; 1 h for single cell binding; 0-10 μg/mL; 30 min for co-binding) specifically binds to HER2 on SK-BR-3 cells (K_d = 11.71 nM) and CD3 on Jurkat cells (K_d = 186.8 nM), and mediates dose-dependent formation of cell aggregates between HER2-positive tumor cells and CD3-positive T cells^[1].
M802 (0-10⁸ pg/mL; 48 h) mediates potent, dose-dependent PBMC cytotoxicity against HER2-positive SK-BR-3, BT-474, NCI-N87 and JIMT-1 tumor cells, while exhibiting extremely low activity against HER2-negative MDA-MB-231 cells and non-cancerous HEK-293 cells^[1].
M802 (0.01-10 μg/mL; 0-6 days) inhibits the proliferation and promotes the apoptosis of HER2-positive SK-BR-3 and BT-474 breast cancer cells in a dose-dependent manner, but has no effect on the proliferation of JIMT-1 cells^[1].
M802 (0.1-10 μg/mL; 24-48 h) dose-dependently modulates the PI3K/AKT and MAPK signaling pathways, inhibits kinase phosphorylation, regulates cyclins, and activates the apoptotic cleavage of caspase-3 in HER2-positive SK-BR-3 and BT-474 breast cancer cells^[1].
M802 (0.0001-10000 ng/mL; 48 h) activates T cells in a dose-dependent manner and induces the secretion of IFN-γ, TNF-α, IL-2 and IL-6 when co-cultured with HER2-positive SK-BR-3 tumor cells and human peripheral blood mononuclear cells (PBMCs)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.